Meihua Buys Dalian Hissen Biopharm for $96.7 Million

Meihua Holdings Group, a China specialty chemical company, will acquire Dalian Hissen Biopharm Co. for $96.7 million. In 2013, Hissen supplied 29% of China’s hepatitis B vaccine. However, because Hissen did not comply with China’s revamped good manufacturing standards (they took effect on December 31, 2013), its manufacturing operation was closed down at the end of last year. More details.... Stock Symbol: (SHA: 600873) Share this with colleagues: // //